# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k070552   
B. Purpose for Submission: New Device   
C. Analyte: Ferritin   
D. Type of Test: Semi-quantitative, Chemiluminescence   
E. Applicant: Dade Behring, Inc.   
F. Proprietary and Established Names: Dimension Vista™ (FERR) Flex $^ \mathrm { \textregistered }$ reagent cartridge Dimension Vista™ LOCI 4 Calibrator

# G. Regulatory Information:

1. Regulation section: 21CFR $\ S 8 6 6 . 5 3 4 0$ Ferritin immunological test system 21CFR $\ S 8 6 2 . 1 1 5 0 $ Calibrator   
2. Classification: Class II   
3. Product Code: DBF-Ferritin, antigen, antiserum, control JIT-Calibrator, secondary   
4. Panel: Immunology (82) Chemistry (75)

# H. Intended Use:

1. Intended use(s): Dimension Vista™ (FERR) Flex $^ \mathrm { \textregistered }$ reagent cartridge- The FERR method is an in vitro diagnostic device for the quantitative measurement of ferritin in human serum and plasma (lithium or sodium heparin, and EDTA) on the Dimension Vista $^ \mathrm { \textregistered }$ System. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (Iron overload) and iron deficiency anemia.

The Dimension Vista™ LOCI 4 Calibrator is an in vitro diagnostic device intended to be used to calibrate the ferritin (FERR) assay on the Dimension Vista™.

2. Indication(s) for use: Same as intended use.

4. Special instrument Requirements:

Dimension Vista $^ \mathrm { \textregistered }$ System

# I. Device Description:

Dimension Vista™ FERR Flex $^ \mathrm { \textregistered }$ reagent cartridge assay is a homogeneous, sandwich chemiluminescent immunoassay using LOCI ™ reagents: Sensibeads (bead reagent coated with streptavidin and containing a photosensitizer dye), Chemibeads (bead reagent coated with murine anti-ferritin monoclonal antibody and containing a chemiluminescent dye), and a biotinylated murine anti-ferritin monoclonal antibody fragment. Buffers, preservatives and stabilizers are also included in the cartridge.

Dimension Vista™ LOCI 4 Calibrator is a five level, liquid calibrator kit consisting of 10 vials (two vials for each level). The product matrix is $6 \%$ bovine serum albumin with buffer, stabilizer, and preservatives. Levels A through E contains ferritin at the following target concentrations: $\mathbf { A } { \sim } 0 ~ \mathrm { { n g / m L } }$ , $\mathrm { B } { \sim } 2 6 ~ \mathrm { \mathrm { n g / m L } }$ , $C \sim 2 1 0$ $\mathrm { n g / m L }$ , $\mathrm { D } { \sim } 1 0 5 0 \mathrm { n g / m L }$ , $\mathrm { E } { \sim } 2 0 0 0 \ \mathrm { n g / m L }$ .

J. Substantial Equivalence Information:

1. Predicate device name(s): Dimension $^ \mathrm { \textregistered }$ Ferritin Flex $^ \mathrm { \textregistered }$ reagent cartridge Dimension $^ \mathrm { \textregistered }$ Ferritin calibrator   
2. Predicate K number(s): k963498 k983548   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Dimension VistaTM FerritinFlex  reagent cartridge(K6440)</td><td rowspan=1 colspan=1>Dimension® Ferritin Flex®reagent cartridge (RF440)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The FERR method is an invitro diagnostic device forthe quantitativemeasurement of ferritin inhuman serum and plasma(lithium or sodium heparin,and EDTA) on theDimension Vista® System.</td><td rowspan=1 colspan=1>The Ferritin Flex® reagentcartridge used on theDimension® clinicalchemistry system with theheterogeneousimmunoassay module is anin vitro diagnostic testintended to quantitativelymeasure ferritin in serumand heparinized plasma.</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Measurements of ferritinaid in the diagnosis ofdiseases affecting ironmetabolism, such ashemochromatosis (Ironoverload) and irondeficiency anemia.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measurement type</td><td rowspan=1 colspan=1>Quantitative</td><td rowspan=1 colspan=1>Same</td></tr></table>

Page 3 of 7   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Dimension VistaTM FerritinFlex ® reagent cartridge(K6440)</td><td rowspan=1 colspan=1>Dimension® Ferritin Flex®reagent cartridge (RF440)</td></tr><tr><td rowspan=1 colspan=1>Capture antibody</td><td rowspan=1 colspan=1>Mouse monoclonal</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reference intervals</td><td rowspan=1 colspan=1>Males 26-388 ng/mLFemales 8-252 ng/mLAll adults 8-388 ng/mL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Stability: Sealed &amp;On-board</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Dimension Vista ® System</td><td rowspan=1 colspan=1>Dimension ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Solid phase</td><td rowspan=1 colspan=1>Chemibeads and Sensibeads</td><td rowspan=1 colspan=1>Ferritin antibody coatedchromium dioxide particles</td></tr><tr><td rowspan=1 colspan=1>Conjugate reagent</td><td rowspan=1 colspan=1>None</td><td rowspan=1 colspan=1>β galactosidase labeled anti-ferritin monoclonalantibody</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>None</td><td rowspan=1 colspan=1>Chlorophenol red-β-d-galactopyranoside</td></tr><tr><td rowspan=1 colspan=1>Detection method</td><td rowspan=1 colspan=1>Chemiluminescence</td><td rowspan=1 colspan=1>Colorimetric</td></tr><tr><td rowspan=1 colspan=1>Measurementabsorbance</td><td rowspan=1 colspan=1>680 and 612 nm</td><td rowspan=1 colspan=1>577 and 700 nm</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum, heparinized andEDTA plasma</td><td rowspan=1 colspan=1>Serum, heparinized plasma</td></tr><tr><td rowspan=1 colspan=1>Sample size</td><td rowspan=1 colspan=1>2 μL</td><td rowspan=1 colspan=1>40 μL</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>0.5 ng/mL- 2000 ng/mL</td><td rowspan=1 colspan=1>1-1000 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Stability: Open</td><td rowspan=1 colspan=1>7 days for wells 1-12</td><td rowspan=1 colspan=1>Varies from 3-10 days</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Dimension VistaTM LOCI 4Calibrator</td><td colspan="1" rowspan="1">Dimension  FerritinCalibrator</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">To calibrate the ferritinmethod</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Composition</td><td colspan="1" rowspan="1">Ferritin from human liver inbovine serum albumin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">ReagentPreparation</td><td colspan="1" rowspan="1">Liquid, Ready-to-use</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">WHO, 3rd IS 94/572</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Levels</td><td colspan="1" rowspan="1">1 without ferritin, 4 withdifferent concentrations offerritin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Stability</td><td colspan="1" rowspan="1">30 days at 2-8°C</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="2" rowspan="1">Differences</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Multi-analyte</td><td colspan="1" rowspan="1">Ferritin</td></tr><tr><td colspan="1" rowspan="1">Instrument system</td><td colspan="1" rowspan="1">Dimension Vista  System</td><td colspan="1" rowspan="1">Dimension® ClinicalChemistry System</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">Frozen -10 to -20°C</td><td colspan="1" rowspan="1">Refrigerated -2 to-8°C</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI Evaluation of Precision Performance of Clinical Devices; Approved Guideline: EP5-A2, CLSI Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline EP9-A2, CLSI Interference Testing in Clinical Chemistry; Approved Guideline EP7-A2. CLSI Evaluation of the Linearity of Quantitative Analytical Methods; Approved Guideline EP6-A.

# L. Test Principle:

The FERR method is a homogenous, sandwich chemiluminescent immunoassay. Ferritin in a sample is incubated with biotinylated murine monoclonal and beads that are coated with anti-ferritin mouse monoclonal and containing a chemiluminescent dye (Chemibeads) to form a particle/ferritin/biotin-antibody sandwich. A second set of beads (Sensibeads), coated with streptavidin and containing a photosensitizer dye is added and bind to the biotin to form bead-pair immunocomplexes. The sample is illuminated at $6 8 0 \mathrm { n m }$ , generating a single oxygen from the Sensibeads that diffuses into the Chemibeads and triggering a chemiluminescent reaction. The resulting signal is measured at $6 1 2 \mathrm { n m }$ and is a direct indication of the ferritin concentration in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Precision testing was done in accordance with CLSI Approved Guideline EP5-A2. Three serum pools and one plasma sample representing the measuring range were analyzed in duplicate, twice a day, for 20 days. Two commercially available controls were also evaluated. The standard deviation (SD) and coefficient of variation $( \% C V )$ for repeatability and within-lab precision are reported below. Overall repeatability was greater than $9 8 \%$ and within-lab reproducibility was greater than $9 6 \%$ .

<table><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Mean(ng/mL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-lab</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Anemia Control Level 1</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>Control Level 2</td><td rowspan=1 colspan=1>161.1</td><td rowspan=1 colspan=1>2.02</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.72</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>SerumPool 1</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 2</td><td rowspan=1 colspan=1>436.4</td><td rowspan=1 colspan=1>5.58</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>14.33</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>1696.3</td><td rowspan=1 colspan=1>27.18</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>57.44</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>Plasma Pool</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>3.1</td></tr></table>

b. Linearity/assay reportable range:

The linear range of the assay $( 0 . 5 - 2 0 0 0 ~ \mathrm { n g / m L ) }$ ) was confirmed by testing five replicates of each dilution (7 total) prepared from a patient serum sample, as described in CLSI protocol EP-6-A. Ferritin concentrations in the sample ranged from 0.0 to $2 1 3 6 . 6 \mathrm { n g / m L }$ . The mean of the observed values for each dilution were plotted versus the expected values. Least squares regression analysis generated the following data:

<table><tr><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Y-intercept(ng/mL)</td><td rowspan=1 colspan=1>Correlation Coefficient</td><td rowspan=1 colspan=1>n</td></tr><tr><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>2.1 ng/mL</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>35</td></tr></table>

Recovery studies were also performed using six serum samples with ferritin concentrations ranging from $4 . 5 \mathrm { ~ - ~ } 1 5 1 ~ \mathrm { n g / m L }$ . Samples were spiked with 10 $\mathrm { n g / m L }$ of ferritin. The percent recovery ranged from $8 7 \%$ to $104 \%$ with a mean recovery of $9 5 \%$ .

c. Traceability (controls, calibrators, or method):

Value assignments for the calibrators are made from a master pool that is referenced to the WHO standard for ferritin $3 ^ { \mathrm { r d } }$ IS 94/572.

d. Detection limit:

The limit of blank was determined from the mean of 20 replicates of the zerolevel calibrator plus 2 standard deviations. The value obtained was 0.13 $\mathrm { { n g / m L } }$ . The limit of blank claim is $0 . 5 ~ \mathrm { { n g / m L } }$ .

e. Analytical specificity:

i. Interference studies: Interference testing was performed according to CLSI Approved Guideline EP7-A2 to determine the effect of various exogenous substances of the Dimension Vista™ FERR method. Minimal interference $( < 1 0 \% )$ was observed when pooled human serum samples representing two concentrations of ferritin $2 0 ~ \mathrm { n g / m L }$ and $5 0 2 . 7 \mathrm { n g / m L }$ ) containing the following interferents were compared to a control without interferent: hemoglobin $( 5 0 0 \mathrm { m g / d L } )$ , unconjugated bilirubin $( 2 0 \mathrm { m g / d L } )$ , conjugated bilirubin $( 6 0 \mathrm { m g / d L } )$ , Intralipid $3 0 0 0 \mathrm { m g / d L } )$ ) rheumatoid factor $( 5 1 0 \mathrm { I U / m L } )$ ). An additional panel of 41 exogenous substances were evaluated for interference and were shown to exhibit minimal interference $( < 1 0 \% )$ .

ii. Cross-reactivity Not applicable.

iii. Antigen excess- The effect of antigen excess in the Dimension Vista™ FERR assay was evaluated using the zero-level calibrator spiked with $2 5 0 , 0 0 0 \mathrm { n g / m L }$ of human ferritin. The test result was reported as “exceeds assay range.” Samples greater than $2 0 0 0 ~ \mathrm { { n g / m L } }$ are reported as exceeding assay range.

f. Assay cut-off: See Expected values/reference range.

2. Comparison studies: a. Method comparison with predicate device:

CLSI Approved Guideline for Method Comparison and Bias Estimation Using Patient Samples; EP9-A2 was followed. The Dimension Vista™ FERR method on the Dimension Vista™ System was compared to the predicate Dimension $^ \mathrm { \textregistered }$ Ferritin Flex $^ \mathrm { \textregistered }$ reagent cartridge on the Dimension $^ \mathrm { \textregistered }$ RxL instrument by assaying 158 serum samples with concentrations ranging from $4 . 4 ~ \mathrm { { n g / m L } }$ to $1 5 7 3 . 3 \mathrm { n g / m L }$ on both systems and comparing the results. Ordinary least squares linear regression statistics are as follows:

<table><tr><td rowspan=1 colspan=1>ComparativeMethod</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Y-Intercept(ng/mL)</td><td rowspan=1 colspan=1>Correlationcoefficient(r)</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>DimensionRxL System</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>1.48ng/mL</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>158</td></tr></table>

Passing-Bablok non-parametric linear regression analysis yielded the following statistics: Slope 1.02 ( $9 5 \%$ CI: 1.00 to 1.03), Y-intercept -0.95 $9 5 \%$ CI -1.81 to -0.47).

b. Matrix comparison:

Ten matched serum, Na-heparin plasma, Li-heparin plasma, EDTA-plasma samples containing ferritin concentrations ranging $5 . 3 - 1 9 7 8 . 5 \mathrm { n g / m L }$ , were assayed and compared. Least squared regression analysis demonstrated that there was no significant bias between the two matrices and yielded the following statistics:

<table><tr><td rowspan=1 colspan=1>Sample typecompared to serum</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Y-intercept</td><td rowspan=1 colspan=1>Correlationcoefficient</td></tr><tr><td rowspan=1 colspan=1>Na-heparin plasma</td><td rowspan=1 colspan=1>1.03</td><td rowspan=1 colspan=1>-2.1</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Li-heparin plasma</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>-4.0</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>EDTA-plasma 1.00</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>-4.6</td><td rowspan=1 colspan=1>1.00</td></tr></table>

3. Clinical studies:

a. Clinical sensitivity: Not applicable.   
$b$ . Clinical specificity: Not applicable.   
c. Other clinical supportive data (when a and b are not applicable): Not applicable.

4. Clinical cut-off: See Expected values/reference range

5. Expected values/Reference range:

The reference intervals were transferred from those previously obtained using the predicate Dimension $^ \mathrm { \textregistered }$ system. They represent the central $9 5 \%$ of results determined from a population of healthy adults $\mathrm { \Delta } ( { \mathrm { n } } { = } 2 9 6$ ; 118 males, and 178 females). The original determination and transference were done in accordance with protocol CLSI C28-A2, How to Define and Determine Reference Intervals in the Clinical Laboratory. Pediatric samples were not evaluated.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>95% Reference Interval</td></tr><tr><td rowspan=1 colspan=1>Males</td><td rowspan=1 colspan=1>26-388 ng/mL</td></tr><tr><td rowspan=1 colspan=1>Females</td><td rowspan=1 colspan=1>8-252 ng/mL</td></tr><tr><td rowspan=1 colspan=1>All adults</td><td rowspan=1 colspan=1>8-388 ng/mL</td></tr></table>

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.